In this study, molecular dynamics (MD) simulations of NMS-P118 in complex with PARP-1 and PARP-2 were performed to understand the molecular mechanism of its selectivity. Alanine scanning together with ...

PARP inhibitors work by working on a DNA repair mechanism that is present in certain fast-growing tumours – blocking the action of the PARP protein that is part of the mechanism causes cancer ...

Olaparib is the only PARP inhibitor that significantly improves overall survival in PSROC, distinguishing it from other PARP inhibitors. All four PARP inhibitors enhance progression-free survival ...

while being much more effective at “trapping” PARP1 to inhibit the DNA damage repair mechanism. “There was a real reason to think that dialling out PARP2 might make PARP inhibitors better ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

Because a subset of these patients actually have DNA damage repair mutations, we know that adding a PARP inhibitor in the setting of progression has been associated with improvements in survival ...

These studies indicate that apoptosis is an important mechanism in viral-induced disease ... cleavage of poly (ADP-ribose) polymerase (PARP) and degradation of ICAD (inhibitor of caspase-activated ...

As such, trials combining capivasertib and ipatasertib with CDK4/6 inhibitors, immune checkpoint inhibitors, and PARP inhibitors are currently ongoing. This review summarizes the available evidence on ...

Discover the role of phytoestrogens, including soy, in menopause management and breast cancer prevention. Learn how these ...

An MTF2-containing subcomplex of Polycomb Repressive Complex 2 promotes cell cycle progression through repression of D-type cyclin expression in certain cellular contexts.

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.